ETR:BIO Biotest Aktiengesellschaft (BIO) Stock Price, News & Analysis €42.40 0.00 (0.00%) As of 04/17/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Biotest Aktiengesellschaft Stock (ETR:BIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BIO alerts:Sign Up Key Stats Today's Range€42.40▼€42.4050-Day Range€40.80▼€42.8052-Week Range€40.40▼€43.40Volume20 shsAverage Volume1,927 shsMarket Capitalization$839.10 millionP/E Ratio10.22Dividend Yield0.09%Price TargetN/AConsensus RatingN/A Company OverviewBiotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.Read More… Receive BIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Email Address BIO Stock News HeadlinesEQS-Adhoc: Biotest AG: Delisting agreement and announced delisting tender offerMarch 31, 2025 | markets.businessinsider.comEQS-Adhoc: Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.March 6, 2025 | markets.businessinsider.comWhat to do with your collapsing portfolio…There might be only one way to save your retirement in this volatile time. After watching investors lose $6 trillion in market cap in a matter of DAYS... And after seeing businesses bleeding dry as trade tensions spiral out of control... What the acclaimed “Market Wizard” Larry Benedict — who beat the market by 103% during the 2008 crash — is about to reveal could not only save your retirement from Trump's tariffs…April 18, 2025 | Brownstone Research (Ad)Aktien»Nachrichten»BIOTEST AKTIE»EQS-Adhoc: Biotest AG veröffentlicht vorläufige Geschäftszahlen 2024 - Prognosen 2024 teilweise übertroffenFebruary 27, 2025 | finanznachrichten.deBiotest Aktiengesellschaft (BIO.DE)February 8, 2025 | finance.yahoo.comEQS-Adhoc: Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchangedNovember 15, 2024 | markets.businessinsider.comBiotest Aktiengesellschaft (BIESF)August 30, 2024 | au.finance.yahoo.comBiotest Aktiengesellschaft (BIO3.F)August 13, 2024 | nz.finance.yahoo.comSee More Headlines BIO Stock Analysis - Frequently Asked Questions How have BIO shares performed this year? Biotest Aktiengesellschaft's stock was trading at €41.20 on January 1st, 2025. Since then, BIO shares have increased by 2.9% and is now trading at €42.40. View the best growth stocks for 2025 here. What other stocks do shareholders of Biotest Aktiengesellschaft own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biotest Aktiengesellschaft investors own include GSK (GSK), Invitae (NVTA), Adaptive Biotechnologies (ADPT), ADMA Biologics (ADMA), Analog Devices (ADI), Adaptimmune Therapeutics (ADAP) and Axcelis Technologies (ACLS). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryMeasuring And Control Equipment Current SymbolETR:BIO CIKN/A Webwww.biotest.com Phone+49-6103-8010FaxN/AEmployees8,200Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)€4.15 Trailing P/E Ratio10.22 Forward P/E Ratio353.33 P/E GrowthN/ANet Income$164.40 million Net Margins9.69% Pretax MarginN/A Return on Equity13.11% Return on Assets8.47% Debt Debt-to-Equity RatioN/A Current Ratio2.54 Quick Ratio1.66 Sales & Book Value Annual Sales$781.30 million Price / Sales1.07 Cash Flow€1.37 per share Price / Cash Flow31.04 Book Value€14.18 per share Price / Book2.99Miscellaneous Outstanding Shares19,790,000Free FloatN/AMarket Cap$839.10 million OptionableNot Optionable Beta0.24 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (ETR:BIO) was last updated on 4/18/2025 by MarketBeat.com Staff From Our Partners🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotest Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share Biotest Aktiengesellschaft With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.